Top Markets
Coin of the day
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.

BML
Xếp hạng trong cổ phiếu #22879
Established in 1944 and headquartered in Lublin, Poland, BIOMED-LUBLIN... Established in 1944 and headquartered in Lublin, Poland, BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. is a biotechnology enterprise engaged in the manufacturing and distribution of pharmaceutical products, medical devices, and laboratory reagents throughout Poland. The company's range of prescription medications includes Distreptaza, utilized in gynecology for addressing chronic inflammatory conditions of the uterine appendages and hemorrhoids. Onko BCG 50 is prescribed for the treatment of superficial (non-muscle invasive) bladder tumors. For passive immunity against hepatitis B, they provide GAMMA anty HBs 200. Additionally, GAMMA anty-D 50 and GAMMA anty-D 150 are Anti D (Rho) immunoglobulin formulations crucial for preventing hemolytic disease in newborns. BioTrombina 400 offers localized control for significant bleeding, and the Anti-Tuberculosis Vaccine BCG 10 is integral to tuberculosis prevention efforts. Beyond pharmaceuticals, BIOMED-LUBLIN supplies a variety of medical and laboratory-grade items. These encompass Ram blood for laboratory applications; Stonebrink medium for the diagnosis of bovine Mycobacterium tuberculosis; and specific Löwenstein-Jensen media, including one adapted for assessing Mycobacterium tuberculosis's drug susceptibility and another containing glycerol for its identification. Their offerings also extend to Ox Thrombin for in-vitro diagnostics and lyophilized preparations, alongside rabbit plasma. Furthermore, the company offers an extensive catalog of reagents. This includes various sera (horse, bovine, calf), essential solutions like trypsin, PBS fluid, Hanks fluid, and Parker's fluid, as well as diverse culture media such as Eagle 1959, RPMI 1640, and Ogawa medium. Completing their reagent portfolio are pseudo cholinesterase, Ox fibrinogen, and rabbit complements.
Giá cổ phiếu
$1.32
Đồng bộ lần cuối: 2023-08-14
Vốn hóa thị trường
$81.94M
Thay đổi (1 ngày)
-0.36%
Thay đổi (1 năm)
0.00%
Quốc gia
PL
Giao dịch BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (BML)

Danh mục

Lịch sử chia tách cổ phiếu của BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (BML)
Cổ phiếu BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (mã: BML) đã trải qua tổng cộng 0 lần chia tách.
Lần chia tách gần nhất diễn ra vào ngày Aug 22, 2026.
Một cổ phiếu BML mua trước ngày Aug 22, 2026 hiện tương đương với 0 cổ phiếu BML.
Danh sách chia tách cổ phiếu
Năm Chia tách Tỷ lệ Tỷ lệ cộng dồn
Không đủ dữ liệu cho ngày được cung cấp.
Chia tách cổ phiếu của các công ty tương tự hoặc đối thủ
Công ty Số lần chia tách cổ phiếu Tỷ lệ cộng dồn Quốc gia
1 x2
US
0 -
NL
0 -
US
1 x3
AU
0 -
CH